About Maibo Pharmaceutical
Maibo Pharmaceutical is a company based in Taizhou (China) founded in 2018. The company has 315 employees as of December 31, 2024. Maibo Pharmaceutical operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Taizhou, China
- Employees 315 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Mabpharm Limited
-
Annual Revenue
$36.05 M (USD)190.7as on Dec 31, 2024
-
Net Profit
-$17.86 M (USD)40.03as on Dec 31, 2024
-
EBITDA
-$8.15 M (USD)59.36as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
315
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Maibo Pharmaceutical
Maibo Pharmaceutical is a publicly listed company on the HKEX with ticker symbol 2181 in Hong Kong, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Maibo Pharmaceutical
Detailed funding history for Maibo Pharmaceutical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Maibo Pharmaceutical
Investment portfolio details for Maibo Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Maibo Pharmaceutical
Detailed financials for Maibo Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Maibo Pharmaceutical Comparisons
Peer comparison for Maibo Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Maibo Pharmaceutical
Maibo Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Maibo Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Maibo Pharmaceutical
Complete news archive for Maibo Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maibo Pharmaceutical
Maibo Pharmaceutical was founded in 2018.
Maibo Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.
Weizhu Qian is the current CEO of Maibo Pharmaceutical.
As of Dec 31, 2024, the latest employee count at Maibo Pharmaceutical is 315.
Annual revenue of Maibo Pharmaceutical is $36.05M as on Dec 31, 2024.
Maibo Pharmaceutical was founded in 2018 and is based in Taizhou, China. Operations focus on the development of biologic drugs within the pharmaceutical sector, targeting cancer and autoimmune conditions. The product pipeline features CMAB007 (Omuzumab), a humanized monoclonal antibody for asthma treatment; CMAB009, intended for colorectal cancer; and CMAB008 (Infliximab), used for autoimmune diseases. Leadership is provided by CEO Weizhu Qian.
Maibo Pharmaceutical's top competitors include Moderna, argenx and Forge Biologics.
Yes, Maibo Pharmaceutical is publicly traded on HKEX under the ticker symbol 2181.
The ticker symbol of Maibo Pharmaceutical is 2181 on HKEX.